Talbot Financial LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Talbot Financial LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 47,266 shares of the company’s stock, valued at approximately $4,066,000.

Several other institutional investors have also recently made changes to their positions in NVO. Westmount Partners LLC increased its holdings in Novo Nordisk A/S by 13.1% in the fourth quarter. Westmount Partners LLC now owns 2,405 shares of the company’s stock valued at $207,000 after buying an additional 279 shares in the last quarter. Salem Investment Counselors Inc. increased its holdings in Novo Nordisk A/S by 2.3% in the fourth quarter. Salem Investment Counselors Inc. now owns 21,926 shares of the company’s stock valued at $1,886,000 after buying an additional 491 shares in the last quarter. Thomasville National Bank increased its holdings in Novo Nordisk A/S by 54.0% in the fourth quarter. Thomasville National Bank now owns 2,933 shares of the company’s stock valued at $252,000 after buying an additional 1,028 shares in the last quarter. Capital Investment Advisors LLC increased its holdings in Novo Nordisk A/S by 12.1% in the fourth quarter. Capital Investment Advisors LLC now owns 4,435 shares of the company’s stock valued at $382,000 after buying an additional 478 shares in the last quarter. Finally, Fiduciary Alliance LLC increased its holdings in Novo Nordisk A/S by 11.4% in the fourth quarter. Fiduciary Alliance LLC now owns 8,107 shares of the company’s stock valued at $697,000 after buying an additional 829 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Down 2.2 %

NVO traded down $1.90 during trading hours on Monday, hitting $84.36. 5,034,926 shares of the company’s stock were exchanged, compared to its average volume of 7,056,390. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The firm has a 50 day moving average of $100.35 and a 200 day moving average of $119.04. The firm has a market cap of $378.57 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.